Study of HRS9531 for sleep apnea and obesity
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an injectable medication (HRS9531) to see if it helps people with both obstructive sleep apnea and obesity. It compares the drug to a placebo (no active medicine) to check safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have obstructive sleep apnea (OSA) confirmed by a sleep test.
- Your BMI is 28 or higher (BMI is a measure of body fat based on your height and weight).
- You have been following a healthy diet and exercise plan for at least 3 months, and your weight has not changed much (no more than 5 kg or 11 pounds) in that time.
- You do not have diabetes, certain heart problems, or a history of pancreatitis or gallbladder disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
This study tests an investigational injectable medication (HDM1005) to see if it can improve sleep apnea and help with weight loss in people who are obese and have obstructive sleep apnea but do not use a CPAP machine. The drug is given by injection and compared to a placebo.
This study tests an investigational medicine (HDM1005) for people who have both obesity and obstructive sleep apnea (where breathing stops during sleep) and who already use a CPAP machine. The goal is to see if the medicine can reduce breathing pauses and improve sleep quality compared to a placebo.
This trial is testing an investigational medication (GZR18) to help people with obesity and obstructive sleep apnea (a condition where breathing stops during sleep) lose weight. It is given alongside the usual positive airway pressure (PAP) therapy, which helps keep the airway open during sleep. The goal is to see if the drug can improve weight and possibly sleep apnea symptoms.
This study tests an investigational medication (IBI362) to see if it can improve sleep apnea in people with obesity. You might qualify if you have moderate to severe sleep apnea and a BMI of 28 or higher, whether or not you currently use a CPAP machine.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
Hear when a new Bstructive Sleep Apnea (OSA) and Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.